REG-Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
Key Highlights
- ➤94% of 221 adults maintained neutralizing antibodies five years after one IXCHIQ dose
- ➤Older adults’ antibody persistence matched younger adults’ responses
- ➤Brazil vaccination campaign administered IXCHIQ to nearly 80,000 adults
- ➤Participants will be followed for up to ten years after vaccination
Expert Statements
Hanneke Schuitemaker, Chief Scientific Officer of Valneva
“These five-year data further reinforce IXCHIQ®'s unique value proposition. For diseases such as chikungunya, where outbreaks are difficult to predict, durable immune persistence following a single dose represents a significant public health advantage. This is particularly important not only for travelers, but also for populations living in endemic regions, many of which are in low- and middle-income countries where access to healthcare and vaccination may be more limited.”
* 94% of participants maintained seroresponse five years after a single vaccination * Comparable antibody persistence observed in older (65+) and younger adults * Data further reinforce IXCHIQ(®)'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ(®). The results demonstrate durable antibody persistence across all age groups evaluated and are consistent with previously reported persistence results(1)(,)(2)(,)(3)(,)(4). The results are in line with Valneva’s expectations for this vaccine, further supporting IXCHIQ(®)'s differentiated profile and its potential to provide long-term protection following a single vaccination, similarly to other live-attenuated vaccines(5)(6).
Get started
Create a free account to read the full story.